Abstract：
Trials evaluating the efficacy of IVF and various treatment options often focus on upstream outcome measures, improvements which may not translate into clinical outcome improvements. A cross-sectional online survey was distributed globally among IVF patients. Respondents were randomised to view one of 16 statements about a hypothetical IVF treatment option called \'FertiSure\', stated to improve one of four upstream outcomes. Statements varied in whether they contained information stating that FertiSure was not proven to improve live-birth rates and about potential risks. Many patients inferred that improvements in upstream outcomes would result in improvements in the probability of live-birth. Nearly 80% of respondents were willing to use FertiSure. Respondents told that FertiSure was not proven to improve live-birth rates and were less willing to use FertiSure. More respondents agreed that FertiSure may pose a risk to patients when they were told this was the case. However, this did not affect their willingness to use FertiSure. Interestingly, 34% of respondents believed FertiSure would not improve the probability of live-birth but were still willing to use it. These results have implications for IVF clinic websites and information about treatment options which may not routinely contain statements about the limited evidence-base and possible risks.
摘要：
评估IVF和各种治疗方案的疗效的试验通常集中在上游结局指标上，可能无法转化为临床结果改善的改善。一项横断面在线调查在全球IVF患者中进行。受访者被随机分为16条关于假想的IVF治疗方案的陈述之一，称为“FertiSure”，声明要改善四个上游成果之一。声明中是否包含说明FertiSure未被证明可以提高活产率和潜在风险的信息。许多患者推断，上游结局的改善将导致活产概率的改善。近80％的受访者愿意使用FertiSure。受访者表示，FertiSure并未被证明可以提高活产率，并且不太愿意使用FertiSure。更多的受访者同意，当他们被告知这种情况时，FertiSure可能会对患者构成风险。然而,这并没有影响他们使用FertiSure的意愿。有趣的是,34％的受访者认为FertiSure不会提高活产的可能性，但仍然愿意使用它。这些结果对IVF诊所网站和有关治疗方案的信息有影响，这些信息可能不经常包含有关有限证据基础和可能风险的陈述。
